000 01376 a2200373 4500
005 20250518043842.0
264 0 _c20200611
008 202006s 0 0 eng d
022 _a1872-8421
024 7 _a10.1016/j.jneuroim.2019.576980
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGill, AlexanderJ
245 0 0 _aA case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes.
_h[electronic resource]
260 _bJournal of neuroimmunology
_c09 2019
300 _a576980 p.
_bdigital
500 _aPublication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAged
650 0 4 _aAntibodies, Monoclonal, Humanized
_xadverse effects
650 0 4 _aAntineoplastic Agents, Immunological
_xadverse effects
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aNivolumab
_xadverse effects
650 0 4 _aParaneoplastic Syndromes, Nervous System
_xblood
650 0 4 _aProgrammed Cell Death 1 Receptor
_xantagonists & inhibitors
700 1 _aPerez, Michael A
700 1 _aPerrone, Christopher M
700 1 _aBae, Charles J
700 1 _aPruitt, Amy A
700 1 _aLancaster, Eric
773 0 _tJournal of neuroimmunology
_gvol. 334
_gp. 576980
856 4 0 _uhttps://doi.org/10.1016/j.jneuroim.2019.576980
_zAvailable from publisher's website
999 _c29794492
_d29794492